Peptides DB
Research-centric peptide and protocol reference hub
Study 42 of 46Orforglipron (LY-3502970) literatureObesity pillars · RCTHigh-impact journal2026

Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.

Orforglipron treatment appears to improve physical and psychosocial functioning in adults with obesity, especially in those with higher BMI and physical limitations.

Read at Obesity pillarsAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
14
Preclinical
9
Observational
1
Open-label
14
Randomised · this one
8
Reviews

Summary and findings

This study evaluated the effects of orforglipron on physical and psychosocial functioning in adults with obesity over 72 weeks. The analysis included patient-reported outcomes from two phase 3 trials, ATTAIN-1 and ATTAIN-2. Participants receiving orforglipron showed improvements in health-related quality of life compared to placebo.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Obesity pillars supplied them

<h4>Background</h4>In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes.<h4>Methods</h4>This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m<sup>2</sup>, ≥35 to <40 kg/m<sup>2</sup>, and ≥40 kg/m<sup>2</sup>) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates.<h4>Results</h4>Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements.<h4>Conclusion</h4>Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.<b>ATTAIN-1: NCT05869903; ATTAIN-2:</b>NCT05872620.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Orforglipron (LY-3502970) corpus

ASafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%reviewAOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanDOrforglipron for Obstructive Sleep Apnea: Research Summary.JAMA · 2026reviewAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanBPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2025 · n=800 · 84.2% preferred Treatment A vs 15.8% for Treatment B.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.Human